covid -19

The expert committee is expected to approve Zydus Cadila’s three-dose COVID-19 vaccine ZyCoV-D for emergency use this week, according to sources.

Union Health Minister Mansukh Mandaviya last week during the question hour in the Rajya Sabha had said, “The government expects that in October-November, four more Indian pharmaceutical companies will start production of indigenous vaccines that will help to meet the domestic demand, Biological E and NSE -1.86 % vaccines will also be available in the market in the coming days, while Zydus Cadila will soon get an emergency use nod from Expert Committee.”

Zydus Cadila last month had said that it has applied for emergency use authorisation (EUA) with the Indian Drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture 10-12 crore doses annually.

The company has conducted the largest clinical trial for its COVID-19 vaccine in India so far in over 50 centers.

The EUA is expected to be given for adults first, though the Drug Controller General of India (DCGI) had earlier asked the Ahmedabad-based firm to return with more data on its ZyCoV-D.

Earlier, during a press briefing, a Member of NITI Aayog Dr V K Paul had said that the DCGI is examining Zydus Cadila’s COVID vaccine for children.

“ZuCoV-D is the first-ever plasmid DNA vaccine for human use, it has proven its safety and efficacy profile in our fight against COVID-19,” MD of Cadila Healthcare Dr Sharvil Patel said.

According to a new study published online in the journal ACS Infectious Disease, a group of medications long used to treat tapeworm has inspired a compound that has shown two-pronged effectiveness against COVID-19 in laboratory studies.

Professor Kim Janda, PhD, the Ely R. Callaway, Jr. Professor of Chemistry, designed the compound, which belongs to a class of molecules known as salicylanilides. Professor of chemistry and director of Scripps Research’s Worm Institute for Research and Medicine in La Jolla, California.

Salicylanilides have been known to work against certain viruses for 10 or 15 years, according to Janda. “However, they tend to be gut-restricted and can have toxicity issues.”

Janda’s compound, on the other hand, overcomes both issues in mouse and cell-based tests, acting as both an antiviral and an anti-inflammatory drug-like compound, with properties that bode well for its use in pill form.

Salicylanilides were first discovered in Germany in the 1950s and used to address worm infections in cattle. Versions including the drug niclosamide are used in animals and humans today to treat tapeworm. They have also been studied for anti-cancer and antimicrobial properties.

The modified salicylanilide compound that Janda created was one of about 60 that he built years ago for another project. When the SARS-CoV-2 virus became a global pandemic in early 2020, knowing that they may have antiviral properties, he started screening his old collection, first in cells with collaborators from Sorrento Therapeutics and The University of Texas Medical Branch, and later, after seeing promising results, working with Scripps Research immunologist John Teijaro, PhD, who conducted rodent studies.

One compound stood out. Dubbed simply “No. 11,” it differs from the commercial tapeworm medicines in key ways, including its ability to pass beyond the gut and be absorbed into the bloodstream — and without the worrisome toxicity.

“Niclosamide is basically digestive-track restricted, and that makes sense, because that’s where parasites reside,” Janda says. “For that reason, simple drug repurposing for a COVID treatment would be counterintuitive, as you want something that is readily bioavailable, yet does not possess the systemic toxicity that niclosamide has.”

About 80 percent of salicylanilide 11 passed into the bloodstream, compared to about 10 percent of the antiparasitic drug niclosamide, which has recently entered clinical trials as a COVID-19 treatment, Janda says.

The experiments showed that of the many modified salicylanilides he had built in his laboratory, No. 11 affected pandemic coronavirus infections in two ways. First, it interfered with how the virus deposited its genetic material into infected cells, a process called endocytosis. Endocytosis requires the virus to form a lipid-based packet around viral genes. The packet enters the infected cell and dissolves, so the infected cell’s protein-building machinery can read it and churn out new viral copies. No. 11 appears to prevent the packet’s dissolution.

“The compound’s antiviral mechanism is the key,” Janda says. “It blocks the viral material from getting out of the endosome, and it just gets degraded. This process does not allow new viral particles to be made as readily.”

Importantly, because it acts inside cells rather than on viral spikes, questions about whether it would work in new variants like Delta and Lambda aren’t a concern, he adds.

“This mechanism is not dependent on the virus spike protein, so these new variants coming up aren’t going to relegate us to finding new molecules as is the case with vaccines or antibodies,” Janda says.

In addition, No. 11 helped quiet potentially toxic inflammation in the research animals, Janda says, which could be important for treating acute respiratory distress associated with life-threatening COVID infections. It reduced levels of interleukin 6, a signaling protein which is a key contributor of inflammation typically found in advanced stages of COVID-19.

Better medications against COVID-19 are urgently needed, as highly infectious new variants drive renewed surges of illness and death globally. But Janda says salicylanilide No. 11 was created long before the pandemic.